Zepbound – The Milli Chronicle

Friday, November 14, 2025

Latest:

Saudi beekeepers harvest highly valued Sidr honey in Najran region
Saudi Arabia’s Yemen reconstruction program signs power deal, expands major infrastructure projects
Saudi doctors successfully separate Jamaican conjoined twins in complex surgery
Obama-Appointed Judge’s Dissent May Strengthen Trump’s Case in Supreme Court Tariff Battle
U.S. Judge Declines to Sanction Buchalter Over AI-Generated Case Citations in Court Filing

Factual Version of a Story

Novo Nordisk and Eli Lilly Reject Claims of Partnership with Mangoceuticals on Obesity Drugs

Novo Nordisk and Eli Lilly clarify that they have no collaboration or special arrangement with telehealth firm Mangoceuticals, following misleading

Featured News World

NewsDesk Milli Chronicle November 6, 2025November 6, 2025 affordable healthcare, American health programs, diabetes care, drug pricing reform, Eli Lilly, GLP-1 medications, healthcare accessibility, injectable treatments, Medicaid access, Medicaid benefits, medical affordability, Medicare coverage, Medicare discounts, Novo Nordisk, obesity treatment, orforglipron, pharmaceutical innovation, prescription savings, public-private partnership, Trump health deal, TrumpRx program, U.S. drug market, U.S. healthcare reform, Wegovy, weight-loss drugs, weight-loss pills, Zepbound

U.S. Strikes Breakthrough Deal to Boost Access to Weight-Loss Drugs

A landmark public-private partnership aims to make life-changing obesity and diabetes treatments more affordable and accessible for millions across America.